During the corresponding time, Foghorn Therapeutics Inc saw a revenue deteriorated by -45.11 % year on year, sequentially revenue fell by -64.67 %. While revenue at the Foghorn Therapeutics Inc 's corporate clients
Foghorn Therapeutics Inc's Comment on Sales, Marketing and Customers
The FDA's regulatory framework for orphan drugs applies to treatments intended for rare diseases or conditions affecting fewer than 200,000 individuals in the United States, or more than 200,000 individuals when recovery of development costs is unlikely. Companies developing orphan products may qualify for incentives such as tax credits and application fee waivers. Orphan drug exclusivity provides a seven-year marketing exclusivity period for the first approved product targeting a specific rare disease or condition, which can prevent competitors from marketing similar products unless clinical superiority is demonstrated. Additionally, the FDA offers expedited development and review programs to facilitate faster access to drugs addressing serious or life-threatening diseases or conditions. The primary market segment includes patients with rare diseases or conditions in the United States.
In a notable development for precision oncology, Foghorn Therapeutics Inc. has announced that the first patient has been dosed with their innovative oral therapeutic agent, FHD-909, during a Phase 1 clinical trial. This first-in-class SMARCA2 selective inhibitor is aimed at addressing solid tumors characterized by mutations in the SMARCA4 gene, with a primary focus on non-small cell lung cancer (NSCLC). This milestone marks a significant step towards optimizing treatment pathways for patients suffering from SMARCA4-mutated cancers, a demographic previously underserved by existing modalities.The Phase 1 trial is designed to assess the safety, pharmacokinetics, and early efficacy of FHD-909, which operates thr...
Unleashing the Power of Precision Medicine: Updates and Future Directions in Foghorn Therapeutics Clinical ProgramPrecision medicine has revolutionized the field of oncology by providing targeted therapies that specifically address the genetic alterations driving cancer growth. Foghorn Therapeutics, a leading biotechnology company, is at the forefront of this exciting frontier. Their groundbreaking work in developing small molecule medicines that selectively modulate gene expression holds great promise for patients with acute myeloid leukemia (AML) and EGFR/KRAS resistance. This article aims to provide an extensive overview of Foghorn Therapeutics recent clinical program updates, research progress, and str...
CAMBRIDGE, Mass., Dec. 01, 2023 - Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company dedicated to correcting abnormal gene expression in the treatment of serious diseases, has exciting news to share. The company announced today that clinical data from the Phase 1 dose escalation study of their groundbreaking drug, FHD-286, will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, on December 9-12, 2023. This data represents a significant breakthrough in the development of a potential new treatment for patients suffering from advanced hematologic malignancies, specifically acute myeloid leukemia (AML) and myelo...
Foghorn Therapeutics Inc’s Comment on Sales, Marketing and Customers
The FDA's regulatory framework for orphan drugs applies to treatments intended for rare diseases or conditions affecting fewer than 200,000 individuals in the United States, or more than 200,000 individuals when recovery of development costs is unlikely. Companies developing orphan products may qualify for incentives such as tax credits and application fee waivers. Orphan drug exclusivity provides a seven-year marketing exclusivity period for the first approved product targeting a specific rare disease or condition, which can prevent competitors from marketing similar products unless clinical superiority is demonstrated. Additionally, the FDA offers expedited development and review programs to facilitate faster access to drugs addressing serious or life-threatening diseases or conditions. The primary market segment includes patients with rare diseases or conditions in the United States.
Sources:
Foghorn Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Foghorn Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Foghorn Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
120.33 %